Skip to main content
Signal8

COMPUGEN LTD (CGEN)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Compugen Ltd. logo

Compugen Ltd.

NASDAQ:CGENHealthcare
-2.72%$1.97
Mkt Cap$186.14M
EV-
Float94.61M
O/S94.73M
VOL132K sh
$ Vol$264K
RVOL0.55×
Inst Own14.8%
SI2.7%
Net Cash/Sh-
Dilution
Compugen Ltd. logoNASDAQ:CGEN$1.97-2.72%
Historical Data
DateOpenHighLowCloseVolume
Nov 18, 20262.002.021.971.97132,019
Nov 17, 20261.992.051.982.02197,679
Nov 16, 20262.062.072.002.04250,429
Nov 13, 20262.112.122.042.10209,644
Nov 12, 20262.042.142.042.12190,239
Nov 11, 20262.092.122.072.09211,132
Nov 10, 20262.132.142.032.09214,917
Nov 9, 20261.962.151.962.14290,497
Nov 6, 20261.881.971.881.96183,992
Nov 5, 20262.002.001.861.92299,932
Nov 4, 20262.032.051.982.03202,920
Nov 3, 20261.982.041.982.01212,670
Nov 2, 20261.972.001.961.98151,473
Oct 30, 20262.022.021.921.98255,459
Oct 29, 20262.022.072.002.04142,900
Oct 28, 20261.962.011.962.01149,269
Oct 27, 20261.921.971.881.97131,409
Oct 26, 20261.951.981.871.88334,470
Oct 23, 20261.971.971.891.94148,021
Oct 22, 20262.112.141.921.96285,546
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
14
HOLD
0
SELL
1
TOTAL15
Insider Trades
InsiderTypeShares
Silberman David profile photoSilberman DavidGrant/Award19.5K
ZWEIFACH SANFORD S profile photoZWEIFACH SANFORD SGrant/Award10.0K
Halevy Gilead profile photoHalevy GileadGrant/Award10.0K
Hukkelhoven Mathias profile photoHukkelhoven MathiasGrant/Award10.0K
Mahler Michelle profile photoMahler MichelleGrant/Award18.0K
Livnat Savitzky Kinneret profile photoLivnat Savitzky KinneretGrant/Award10.0K
Shareholders
14.8%
Institutional
(79)
0.4%
Insiderⓘ
(12)
0.0%
5%+ Owners
(0)
84.8%
Unattributed (incl. retail)ⓘ
Institutional14.8%
Insider0.4%
Unattributed (incl. retail)84.8%
Sources: 13F, Form 4, 13D/13GO/S: 94.7M · as of 30 Jul 2026 · SEC filings
Insiders & Institutional Holders
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.

The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets.

The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.

It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Key Metrics
Market Cap$186.14M
Enterprise Value--
P/E Ratio7.58
Est. Net Cash/Share--
Institutional Ownership14.75%

based on 94.73M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryILIL
IPO DateAug 11, 2000
Shares Outstanding94.73M
Authorized Shares
Float94.61M
52-Week Range
$1.43$3.23
$1.97(30th percentile)
Volume
Average Daily Volume241.12K
131.74K today vs 241.12K avg(-45%)

30d Avg

241.12K

60d Avg

211.65K

90d Avg

226.95K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of CGEN as of Dec 31, 2025 records an effective F-3 shelf registration (effective Jun 8, 2026) and an at-the-market sales agreement dated Jan 31, 2023, from SEC filings. Compugen Ltd (NASDAQ: CGEN) traded at $1.97 on Nov 18, 2026, down 2.72% from the previous close of $2.02. 52-week range: $1.43 to $3.24. The company is in the Healthcare sector (Biotechnology).